Yahoo Finance

Insider Ownership: 23.2%

Earnings Growth Forecast: 27.3% p.a.

Guangdong Haomei New Materials reported strong earnings growth for the first nine months of 2024, with net income rising to CNY 171.81 million from CNY 124.26 million a year ago. The company completed a share buyback, enhancing shareholder value by repurchasing shares worth CNY 45 million. Despite past shareholder dilution, it trades at a favorable price-to-earnings ratio of 22.2x compared to the CN market average and forecasts significant profit growth exceeding market expectations over the next three years.

• Dive into the specifics of Guangdong Haomei New MaterialsLtd here with our thorough growth forecast report.

• According our valuation report, there's an indication that Guangdong Haomei New MaterialsLtd's share price might be on the cheaper side.

Inner Mongolia Furui Medical Science

Simply Wall St Growth Rating: ★★★★★☆

Overview: Inner Mongolia Furui Medical Science Co., Ltd. operates in the medical industry and has a market capitalization of approximately CN¥9.84 billion.

Operations: Revenue segments for the company are not provided in the available text.

Insider Ownership: 17.3%

Earnings Growth Forecast: 47.1% p.a.

Inner Mongolia Furui Medical Science has demonstrated robust earnings growth, with net income increasing to CNY 102 million for the first nine months of 2024, up from CNY 73.16 million a year earlier. The company's revenue also grew significantly, reaching CNY 979.86 million from CNY 807 million in the same period last year. Despite a highly volatile share price recently, its earnings are forecast to grow substantially faster than the Chinese market average over the next three years.

• Delve into the full analysis future growth report here for a deeper understanding of Inner Mongolia Furui Medical Science.

• Our valuation report here indicates Inner Mongolia Furui Medical Science may be overvalued.

Turning Ideas Into Actions

• Embark on your investment journey to our 1522 Fast Growing Companies With High Insider Ownership selection here.

• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1405 SZSE:002988 and SZSE:300049.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com